Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Drug: Pacritinib for Myelofibrosis - Altai Oncology

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara

New Drug: Pacritinib for Myelofibrosis

New Drug: Pacritinib for Myelofibrosis
  • International, multicenter, randomized, double-blind trial (PERSIST-2)
  • Intermediate-1, intermediate-2, or high-risk disease myelofibrozis
  • Pacritinib 400 mg (n=75) vs pacritinib 200 mg BID (n=74) vs BAT (n=72
  • >35% spleen volume reduction: 18% vs. 22% vs. 3% (p=0.001)
  • Symptom reduction: 32% pacritinib BID vs. 14% BAT (p-0.01)
  • OS not statistically different between groups
  • Non-hematologic AEs for pacritinib: gastrointestinal events, fatigue, peripheral edema, and dizziness
  • Non-hematologic AEs for BAT: abdominal pain, fatigue, diarrhea, and peripheral edema

JAMA Oncol. 2018;4(5):652-659

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis


Reviewed by Hasan Cagri Yildirim

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More